3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neurofibromatosis 2
1
Neoplasms
1
Neoplasm Metastasis
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Radiosurgery
33
Radiotherapy
19
Temozolomide
16
Magnetic Resonance Spectroscopy
12
Surgical Procedures, Operative
7
Cyclophosphamide
7
trastuzumab deruxtecan
4
temsirolimus
4
Sunitinib
4
Specimen Handling
4
Mental Status and Dementia Tests
4
motexafin gadolinium
3
fludarabine phosphate
3
fludarabine
3
aldesleukin
3
Trastuzumab
3
Pemetrexed
3
Fluorodeoxyglucose F18
3
Erlotinib Hydrochloride
3
Dexamethasone
3
Capecitabine
3
Bevacizumab
3
pembrolizumab
2
entrectinib
2
efaproxiral
2
Vinorelbine
2
Topotecan
2
Sorafenib
2
Radiotherapy, Intensity-Modulated
2
Quality of Life
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
Doxycycline
×
CNS
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn